Grown Kidneys. Fit All. The Start. All Organs

SCIENTISTS 

Grown Kidneys. Fit All. The Start. All Organs 

BRITISH COLUMBIA 

Scientists have successfully engineered the world's first 'universal' kidney by using enzymes to strip blood-type markers, potentially ending the life-threatening wait for matching organ donors.

In a groundbreaking medical trial, researchers from Canada and China have utilized specialized enzymes to strip the blood-type markers from a donated Type A kidney, effectively converting it into a 'universal' Type O organ. The modified kidney was transplanted into a brain-dead patient with family consent, where it functioned successfully for several days. This experiment marks a historic bridge between laboratory science and clinical care, proving that it is possible to 'cloak' an organ's identity to prevent immediate immune rejection due to blood-type incompatibility.

The implications for the global organ shortage are massive. Currently, 11 people die every day in the U.S. waiting for a kidney, and those with Type O blood often face the longest wait times because they can only receive organs from Type O donors. While this study noted that blood-type markers began to reappear by the third day, the significantly reduced immune response provides a roadmap for the future. Perfecting this technology could eliminate the need for costly immunosuppression and months of preparation, turning every donated kidney into a potential match for any patient on the waitlist.

source: University of British Columbia. (2025). UBC enzyme technology clears first human test toward universal donor organs for transplantation. Nature Biomedical Engineering.

What are your thoughts on this incredible breakthrough? How do you think this could change the future of medicine?

Disclaimer: This content is for informational and educational purposes only.

Researchers at the University of British Columbia (UBC) and Avivo Biomedical have achieved the first successful conversion of a donor kidney from blood type A to the universal type O, enabling compatibility across all blood types. Using specialized enzymes to remove antigens, this "enzyme-converted type-O (ECO)" kidney prevents immediate rejection, potentially eliminating donor shortages. 

Key Breakthrough Details

• Methodology: Researchers applied enzymes as "molecular scissors" to strip away the A-type sugar antigens from the kidney, turning it into a universal O-type organ.

• Success of Transplant: In a groundbreaking, peer-reviewed study, this converted type-A kidney was successfully transplanted into a blood-type mismatched recipient.

• Reduced Rejection: The study demonstrated that the modified kidney worked properly without triggering hyperacute rejection (the rapid, fatal immune response typical of mismatched transplants).

• Impact on Waiting Lists: This technology aims to make more donor organs available, specifically for type O patients, who often face the longest wait times. 

Key Takeaways

• The Problem: Over 100,000 Americans and thousands of Canadians are on waiting lists, but many organs go unused due to blood-type mismatches, say Agappe Diagnostics.

• The Solution: The enzyme-driven approach changes the organ, rather than treating the recipient's immune system, offering a faster and more effective option.

• Future Work: While this is a major milestone, further research is ongoing, with researchers monitoring for potential re-growth of antigens, says this YouTube video. 

This breakthrough was published in Nature Biomedical Engineering in October 2025. 

FOR 2027-2030 & ONWARD 

This with Wolves of Chernobyl & DNA Mutation. Beyond mRNA crisper 

Proteins - Hormones. Disease eradication. 

Extended life from averages 50-80 to 80-250+ 

We will have solutions for 90% or up to 99% of all biological concerns connected to atmospheric preservation while staying ahead of bacterial & warfare efforts with environmental aspects 

The Wolf of Chernobyl is a cancer of almost all vaccine almost complete yet in H.I.3 our introduction is different than conveyor cancer treatment 

Chernobyl wolves have developed remarkable resilience to high radiation levels, showing genetic adaptations that act as a protective shield against cancer. Research indicates these wolves, exposed to doses 6 times the human safety limit, possess altered immune systems similar to cancer patients undergoing radiation therapy, allowing them to thrive by adapting to chronic environmental stress. 

Key Findings on Chernobyl Wolf Immunity

• Genetic Adaptation: Studies by evolutionary biologist Cara Love and her team found that Chernobyl wolves have developed specific genetic mutations that increase their chances of surviving cancer.

• Immune System Changes: The wolves’ blood chemistry has shifted, revealing immune systems that are better at managing cancer, with 23 identified genes showing protective, anti-tumor effects.

• Rapid Evolution: Due to constant, high-level exposure, the wolves are undergoing accelerated natural selection, where individuals with better-adapted genes survive and reproduce.

• Resilience Mechanism: While the wolves are still exposed to high radiation, their DNA and immune systems have adapted to cope with the damage, making them less likely to succumb to cancer, despite the environmental pressure.

• Not Just "Mutants": The researchers emphasize that these are not merely "mutants" in a sci-fi sense, but rather a population that has biologically adapted to survive in a high-radiation, human-free environment. 

BLOOD PROCEDURES TO REPAIR BODY

Replacing tainted blood involves medical procedures designed to remove contaminated or diseased blood and replace it with safe blood or plasma, most notably used in response to historical public health crises, such as the 1980s-1990s tainted blood scandal, where thousands were infected with HIV and hepatitis C through blood products. 

Here are the key aspects of replacing tainted blood:

• Exchange Transfusion: This is the primary procedure, which involves removing the patient's blood (or blood components) and replacing it with donated blood or plasma to treat life-threatening conditions or blood toxicities.

• The Tainted Blood Scandal (1980s-90s): During this period, HIV and hepatitis C contaminated the blood supply, leading to mass infections, particularly among hemophiliacs. This forced massive reforms in blood collection, resulting in the creation of independent, safer blood authorities like Canadian Blood Services.

• Modern Safety Measures: Following the Krever Inquiry, the current blood system utilizes rigorous screening, viral inactivation methods (like dry heating and solvent detergent treatment), and donor deferral to ensure blood safety.

• Alternative Solutions:

• Recombinant Factor Concentrates: To treat hemophilia safely, synthetic (recombinant) clotting factors are now used, which carry zero risk of blood-borne pathogen transmission.

• Artificial Blood Research: Scientists are developing hemoglobin-based oxygen carriers (HBOCs) and synthetic blood substitutes (e.g., from stem cells) to eventually replace the need for human blood, aiming to eliminate disease risks and blood type matching, though none are currently FDA-approved for general use.

• Compensation and Support: Governments have established, or are in the process of creating, compensation schemes and support for individuals who received tainted blood, such as the Infected Blood Compensation Authority in the UK. 

Blood Replacement Timeframes (Post-Donation):

• Plasma: The body replaces blood volume (plasma) within 24 hours

• Red Blood Cells: These take 4-6 weeks to fully replenish.

• Iron: Lost iron is replaced over 6-8 weeks. 

Honeybee venom shows power to wipe out aggressive breast cancer cells

In a discovery that blends nature’s brilliance with medical science, researchers have found that honeybee venom can destroy 100% of aggressive breast cancer cells in less than 60 minutes. At the heart of this breakthrough is melittin, a remarkable substance within the venom that attacks cancer cells by punching holes in their protective walls, leaving most healthy cells untouched.

This finding is extraordinary because aggressive breast cancers, such as triple-negative types, are notoriously difficult to treat. Traditional methods like chemotherapy often damage healthy tissue while still struggling to fully eliminate resistant cancer cells. Melittin, however, acts with precision, directly targeting the cancer’s defences and breaking them down from within.

In laboratory studies, the venom’s effects were rapid and decisive, wiping out cancer cells while causing minimal harm to surrounding healthy tissue. Researchers are now working to understand how melittin could be harnessed safely in future treatments—whether on its own or combined with existing therapies. If successful, it could mark the beginning of a completely new class of cancer treatments inspired by the natural world.

What makes this discovery so inspiring is the reminder that solutions to some of our greatest medical challenges may be hiding in plain sight. Bees, already essential for pollination and sustaining life on Earth, may also hold the key to unlocking life-saving medicines. It is a humbling thought that the cure humanity has been chasing might have been buzzing all around us.

While more research is needed before bee venom treatments become widely available, this breakthrough offers real hope. It highlights how nature can provide unexpected answers and how scientific curiosity can transform those answers into powerful tools for healing.

The next time you see a bee, remember—they are not only keepers of our food supply but may also be silent guardians of human health.

What other examples of medicine from nature come to mind? Does this discovery change how you see bees?

Disclaimer: This content is for informational and educational purposes only.

Science 

https://www.facebook.com/share/1HzFJPqhQ8/

Carl “Alfalfa” Switzer captured the hearts of a generation as the lovably off-key, cowlick-sporting Alfalfa in the beloved Our Gang (later The Little Rascals) comedies. With his crooked grin, signature hair, and hilariously earnest singing—often punctuated by a finger-wag and a high-pitched warble—he became one of the most iconic child stars of the 1930s.

Born in Paris, Illinois, in 1927, Carl and his older brother Harold were discovered at a talent show and signed to Hal Roach Studios in 1935. While Harold stepped away from acting by 1940, Carl’s star kept rising. As Alfalfa, he stole scenes with a mix of bravado and vulnerability—whether serenading Darla with “I’m in the Mood for Love” (badly), squaring off with Spanky, or dreaming of stardom under his backyard “stage.” His charm was genuine, his timing instinctive.

Behind the camera, he was energetic and mischievous—prone to pranks and occasional scuffles, much of which the press sensationalized. But those who worked with him often recalled his quick wit, loyalty, and natural charisma.

After Our Gang ended in 1940, Carl continued acting—appearing in films like Henry and Dizzy (1942), Rosie the Riveter (1944), and the Gas House Kids series. You can spot him in It’s a Wonderful Life (1946) as the young man who pulls back the gym floor to reveal the swimming pool—a joyful, fleeting moment in a classic.

As an adult, Carl struggled to transition out of the shadow of his childhood fame. He took bit parts (often uncredited), had run-ins with the law, and faced personal setbacks—including two brief marriages. Yet he also built a quieter, meaningful life behind the scenes: becoming a respected hunting guide and dog trainer, counting stars like Jimmy Stewart and Roy Rogers among his clients. He even appeared on The Roy Rogers Show, sometimes with his own well-trained dogs.

His final screen role was a small but notable one: a Hebrew slave in Cecil B. DeMille’s The Ten Commandments (1956)—a film that would go on to win the Academy Award for Best Picture.

Tragically, Carl’s life ended far too soon. On January 21, 1959, at age 31, he was fatally shot during a dispute in Mission Hills, California—over an unpaid $50 fee for training a dog. The incident was later ruled justifiable homicide, a legal verdict that could not soften the loss of a man still seeking his second act.

Though his story is often reduced to its sad ending, those who knew him—and those who grew up laughing with Alfalfa—remember a bright, complicated, deeply human soul who brought joy to millions.

(Note: Carl Switzer was cremated following his death. His ashes were given to his mother, and no public burial site exists.)

#fblifestyle

A team of scientists from the University of Nottingham has developed a special gel that can regrow damaged tooth enamel, offering a simpler and less painful way to repair teeth. Enamel, the hard outer layer that protects our teeth, cannot naturally regenerate once it wears away. The new gel mimics the body’s natural enamel-forming process, helping new enamel crystals grow exactly where the old ones were lost. This discovery could transform dental care by allowing dentists to repair decay without drilling or fillings.

The gel uses synthetic proteins called elastin-like recombinamers, which act as a scaffold similar to natural proteins used during tooth development. When applied to worn or demineralized enamel, the gel triggers the growth of new enamel crystals that perfectly align with the original structure. In lab tests, the regenerated enamel proved to be just as strong and durable as healthy enamel, even when exposed to brushing, chewing, and acidic foods.

Researchers say this breakthrough could eventually allow dentists to restore enamel in a single, simple procedure. It also outperformed current enamel-repair methods and could become a key tool against tooth decay worldwide. Although human trials are still needed, early results suggest this “enamel-regrowing” gel could bring regenerative dentistry closer to reality, giving patients a natural, long-lasting fix for damaged teeth.

What are your thoughts on this potential breakthrough? Could this change how we approach dental care in the future?

Disclaimer: This content is for informational and educational purposes only.

A revolutionary cancer treatment may be on the horizon as researchers from three major American universities have discovered a way to destroy cancer cells using light alone. This breakthrough technique does not require chemotherapy or drugs and has shown an astonishing 99 percent success rate in early trials.

The method relies on a process called photodynamic therapy, where specific wavelengths of light are directed at cancer cells. When exposed, the cells become destabilised and break apart, leaving surrounding healthy tissue unharmed. Unlike chemotherapy, which often damages both healthy and cancerous cells, this light based approach targets tumours with remarkable precision.

Scientists believe this innovation could change the future of cancer treatment, making therapies safer, less invasive, and far more effective. Patients could potentially avoid the painful side effects of chemo while receiving a treatment that is faster and highly accurate.

While more testing is needed before this becomes widely available, the success rate reported in early studies has already caught global attention. Experts are calling it one of the most promising cancer breakthroughs in decades.

This discovery brings hope that light itself could become one of medicine’s most powerful tools in the fight against cancer.

What are your thoughts on this potential new therapy? How could targeted treatments like this change medicine in the future?

Disclaimer: This content is for informational and educational purposes only.

First human trial for a new cancer drug may finally crack the gene that drives 70% of all cancers

A brand-new cancer drug called PMR-116 is heading into its first human trial in 2025 — and it’s going after one of cancer’s biggest troublemakers: the MYC protein. MYC is involved in about 70% of cancers, including tough ones like ovarian, breast, pancreatic, prostate, liver, and stomach cancer. When MYC goes into overdrive, it makes tumors grow faster and harder to treat, which is why scientists have been desperate to stop it.

The problem? MYC’s shape makes it almost impossible to target directly. PMR-116 takes a smarter route — instead of hitting MYC itself, it blocks the process MYC needs to make growth-boosting proteins. In animal tests, that cut prostate cancer lesions by 85% and slowed tumor growth within just half a day.

The upcoming “basket trial” will include people with different MYC-driven cancers whose current treatments have stopped working. If this works in humans, it could finally give doctors a way to switch off one of cancer’s most stubborn drivers.

RESEARCH PAPER 
DOI: 10.1158/1538-7445.PRCA2023-PR006

What are your thoughts on this indirect approach to targeting cancer? What other medical breakthroughs are you following?

Disclaimer: This content is for informational and educational purposes only.

https://www.facebook.com/share/1EcTQqspwA/

26. K.T-CIG